Infinity Pharmaceuticals Given Consensus Recommendation of “Buy” by Analysts (NASDAQ:INFI)
Infinity Pharmaceuticals (NASDAQ:INFI) has earned an average recommendation of “Buy” from the nine brokerages that are covering the stock, Analyst Ratings.Net reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $16.63.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) opened at 10.84 on Wednesday. Infinity Pharmaceuticals has a 52 week low of $8.40 and a 52 week high of $21.60. The stock’s 50-day moving average is $10.95 and its 200-day moving average is $11.56. The company’s market cap is $526.2 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Tuesday, August 5th. The company reported ($0.78) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.84) by $0.06. During the same quarter last year, the company posted ($0.68) earnings per share. Infinity Pharmaceuticals’s revenue was up NaN% compared to the same quarter last year. On average, analysts predict that Infinity Pharmaceuticals will post $-3.47 earnings per share for the current fiscal year.
INFI has been the subject of a number of recent research reports. Analysts at William Blair upgraded shares of Infinity Pharmaceuticals to an “outperform” rating in a research note on Wednesday. Analysts at Morgan Stanley initiated coverage on shares of Infinity Pharmaceuticals in a research note on Wednesday, June 25th. They set an “overweight” rating and a $17.00 price target on the stock.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.